DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 168,210 shares of the medical device company’s stock after selling 8,385 shares during the period. Public Employees Retirement System of Ohio’s holdings in DexCom were worth $23,331,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. DSM Capital Partners LLC acquired a new position in DexCom during the 4th quarter worth $28,000. Crewe Advisors LLC acquired a new position in DexCom during the 1st quarter worth $29,000. Valley National Advisers Inc. grew its holdings in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares in the last quarter. Riverview Trust Co acquired a new position in shares of DexCom in the 1st quarter valued at about $32,000. Finally, MV Capital Management Inc. boosted its holdings in shares of DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after buying an additional 138 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 659 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $114.29, for a total value of $75,317.11. Following the sale, the executive vice president now directly owns 66,901 shares in the company, valued at approximately $7,646,115.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the transaction, the director now directly owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 659 shares of DexCom stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the transaction, the executive vice president now directly owns 66,901 shares in the company, valued at $7,646,115.29. The disclosure for this sale can be found here. Insiders have sold 4,112 shares of company stock worth $480,861 in the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $145.00 price target on shares of DexCom in a report on Tuesday, July 23rd. UBS Group decreased their price target on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday. Wells Fargo & Company decreased their price target on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a report on Friday. Piper Sandler decreased their price target on shares of DexCom from $150.00 to $90.00 and set an “overweight” rating for the company in a report on Friday. Finally, JPMorgan Chase & Co. lowered shares of DexCom from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $145.00 to $75.00 in a report on Friday. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $111.50.

DexCom Price Performance

Shares of NASDAQ DXCM traded up $3.48 during midday trading on Monday, reaching $67.48. The company’s stock had a trading volume of 18,274,066 shares, compared to its average volume of 3,363,822. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The company has a 50 day moving average price of $115.28 and a 200 day moving average price of $123.76. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a market cap of $27.04 billion, a price-to-earnings ratio of 42.83, a price-to-earnings-growth ratio of 1.58 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the previous year, the firm earned $0.34 EPS. The business’s revenue for the quarter was up 15.3% on a year-over-year basis. On average, equities research analysts expect that DexCom, Inc. will post 1.76 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.